You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Journal club
CFTR potentiator for cystic fibrosis
  1. Siu P Cho
  1. Correspondence to Dr Siu P Cho, ST3, East Kent Hospitals University NHS Foundation Trust, Kent and Canterbury Hospital, Department of Chest Medicine, Ethelbert Road, Canterbury CT1 3NG, UK; pete.sp.cho{at}gmail.com

https://doi.org/10.1136/thoraxjnl-2011-201512

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This multicentre, double blinded, randomised controlled trial assessed the efficacy of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) protein potentiator.

    The primary outcome of the trial was the change in the forced expiratory volume in 1 s (FEV1). The secondary outcomes were time to the first pulmonary exacerbation and subject-reported respiratory symptoms. The trial …

    View Full Text